Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3033 First-in-Korea Clinical Trial of Lu-177-DOTATATE in Patients with Inoperable, Progressive Somatostatin Receptor-Positive, Metastatic or Locally Advanced Neuroendocrine Tumor (SNU-KB-01)

Introduction: Peptide receptor radionuclide therapy (PRRT) based on Lu-177 DOTATATE is currently used worldwide as a treatment option for neuroendocrine tumor patients. But until now, no PRRT has been approved by the Korea Food and Drug Administration (KFDA). Thus, neuroendocrine tumor patients in Korea have severely limited access to the treatment. To provide treatment opportunities, we have planned a First-in-Korea phase I clinical trial of SNU-KB-01, no-carrier added Lu-177 labeled DOTATATE.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Suh M, Cheon G, Lee D,

Keywords: PRRT, clinical trial, Neuroendocrine tumor, Lu-177-DOTATATE,

#3019 Incomplete Peptide Receptor Radionuclide Therapy Courses - Are We Selecting Our Patients Appropriately?

Introduction: As per recommendations, a Peptide Receptor Radionuclide Therapy (PRRT) with Lu-177 DOTATATE course usually consists of 4 cycles. Patients may discontinue a PRRT course early, either due to progression or toxicity. Limited data are available about predictive factors for PRRT early discontinuation.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Julian G

Authors: Gertner J, Groves J, Aziz B, Miah L, Furtado O'Mahony L,

Keywords: prrt,

#2917 Quantification of Intratherapeutic SPECT/CT for Lutetium-177-DOTATOC PRRT in Neuroendocrine Tumors

Introduction: In PRRT for NET, feasibility of lesion uptake quantification in Lu-177-DOTATOC SPECT/CT for therapy monitoring remains unclear.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Galler M, Schatka I, Buch F, Bluemel S, Jann H,

Keywords: Lu-177-DOTATOC, PRRT, NET, dosimetry, SPECT/CT, Quantification,

#2900 Radionuclide Therapy in the Continuum of Care of Neuroendocrine Tumors: Results of the SEPTRALU Study

Introduction: Peptide receptor radionuclide therapy (PRRT, Lu-177-DOTATATE) is safe and effective in neuroendocrine tumors (NET). However, the best sequence of administration is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Mitjavila Casanovas M, Carmona-Bayonas A, Pubul V, García-Cañamaque L, Aller J,

Keywords: Lu-177-DOTATATE, radionuclide, survival, treatment,

#2838 Accidental Injection of Unlabeled Lu-177 Caused Catastrophic Consequences in Patients with Neuroendocrine Tumor

Introduction: Since Lu-177 DOTATATE treatment is not approved in South Korea, patients with neuroendocrine tumors were sent to Germany and Malaysia for the treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Kang K, Song Y, Kwon T, Ha W, Jin Y,

Keywords: radiation accident, PRRT, neuroendocrine tumor,